日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval

新冠肺炎康复者血浆安全性和有效性分析,用于生物制品许可申请审批

Sullivan, David J; Reik, Rita; Prichard, Alicia; Pagan, Marlene; Tobian, Aaron A R; Caturegli, Patrizio; Pekosz, Andrew; Klein, Sabra L; Bloch, Evan M; Shoham, Shmuel; Gebo, Kelly A; Joyner, Michael J; Senefeld, Jonathon W; Franchini, Massimo; Focosi, Daniele; Pandey, Suchitra; Lane, Karen; McBee, Nichol A; Pirofski, Liise-Anne; Casadevall, Arturo; Hanley, Daniel F

Heightened Nontesting Risk Mitigation Blood Donor Screening with Retrospective Transcription-Mediated Amplification Testing during a 2023 Autochthonous Florida Malaria Cluster

在2023年佛罗里达州本土疟疾聚集性疫情期间,通过回顾性转录介导扩增检测加强对献血者进行非检测风险缓解筛查。

Sullivan, David J; Lanteri, Marion C; Bres, Vanessa; Hanhan, Maesa; Pagan, Marlene; Rey, Alejandro; Thomas, Korena; Reik, Rita A

Limited genome evolution of Cryptococcus neoformans following an accidental infection in the research laboratory

研究实验室意外感染后,新型隐球菌的基因组进化受到限制

Fan, Yunfan; Kulkarni, Madhura; Zhang, Sean X; Timp, Winston; Sullivan, David J; Smith, Daniel F Q; Casadevall, Arturo; Hardwick, J Marie

Guidance on the management of asymptomatic blood donors who test positive for Babesia

关于对巴贝虫病检测呈阳性的无症状献血者进行管理的指导

Bloch, Evan M; Jacobs, Jeremy W; Vannier, Edouard; Wormser, Gary P; Gelfand, Jeffrey A; Sikand, Vijay K; Heller, Howard M; Sood, Sunil K; Kirkman, Laura; Johnson, Jennie E; Marcos, Luis A; Lemieux, Jacob E; Smith, Robert P; Woolley, Ann E; Perry, Whitney A; Polgreen, Philip M; Beekmann, Susan E; Sullivan, David J; Auwaerter, Paul G; Krause, Peter J

A nonclassical pathway of β-hematin crystal nucleation enables its suppression by antimalarials

β-血红素晶体成核的非经典途径使其能够被抗疟药抑制。

Ma, Wenchuan; Verma, Lakshmanji; Lee, Huan-Jui; Pan, Weichun; Sherman, Michael B; Sullivan, David J; Rimer, Jeffrey D; Palmer, Jeremy C; Vekilov, Peter G

Cethromycin pharmacokinetics and pharmacodynamics for single dose cure of Plasmodium berghei liver stages

塞曲霉素单剂量治疗伯氏疟原虫肝期感染的药代动力学和药效学研究

Kennedy, Grace; West, Rachel M; Poti, Kristin; Bobb, Bryce; Ippolito, Matthew M; Marzinke, Mark A; Kaludov, Nikola; Sullivan, David J Jr

Fractional curative killing of pyronaridine or artesunate combinations with tafenoquine, 4-aminoquinolines, or azithromycin in a murine malaria-luciferase model

在小鼠疟疾-荧光素酶模型中,吡咯萘啶或青蒿琥酯与他非诺喹、4-氨基喹啉或阿奇霉素联合用药的部分治愈性杀灭作用

Lee, Gayoung; Aneke, Janessa Sochima; Sullivan, David J Jr

Stage-specific pharmacodynamic chloroquine and pyronaridine action on artemisinin ring-stage resistant Kelch C580Y mutation Plasmodium falciparum correlates to hemozoin inhibition process.

氯喹和吡咯萘啶对青蒿素环状期耐药的Kelch C580Y突变恶性疟原虫的阶段特异性药效作用与血红素抑制过程相关

Sayeed Abeer, Atkinson Revie, Vekilov Peter G, Rimer Jeffrey D, Sullivan David J

The hematin-dihydroartemisinin adduct mobilizes a potent mechanism to suppress β-hematin crystallization

血红素-双氢青蒿素加合物激活了一种抑制β-血红素结晶的有效机制

Azargoshasb, Hamidreza; Lee, Huan-Jui; Sullivan, David J; Rimer, Jeffrey D; Vekilov, Peter G

A Rapid Systematic Review of U.S. Food and Drug Administration-authorized COVID-19 Treatments

对美国食品药品监督管理局批准的COVID-19疗法的快速系统评价

Sullivan, David J; Franchini, Massimo; Joyner, Michael J; Casadevall, Arturo; Focosi, Daniele